PitchBook’s latest report on the pharmaceutical biotools sector shows a market in transition, and not a quiet one.
Investment is bouncing back in a big way, fuelled by AI-powered platforms, multi-omics, and lab automation.
But while the funding surge feels promising, exits are telling a different story. IPOs are nearly absent, M&A is doing the heavy lifting, and VC bets are increasingly consolidating around mature, IP-rich platforms.
If you’re tracking where the money is flowing, and where the exits aren’t, this breakdown of PitchBook’s 2025 data is a must-read.
Let’s get into the numbers, trends, and strategic shifts reshaping this vital corner of healthtech.
Q1 2025 funding highlights: Big money, fewer bets
After a shaky 2022–2023, it looks like pharma biotools funding is finding its footing.
Q1 2025 delivered a clear rebound, with $1.3 billion raised in 65 deals. That’s an 81.4% jump from Q4 2024 and the highest funding level since Q2 2024.
Sounds like a comeback, right?
Yes, but with a twist!
While money is flowing again, the deal count is shrinking. Over the past 12 months, the number of transactions dipped by 9.5% (to 238 deals), yet total funding climbed 12.8% to $4.8 billion.
Investors are chasing bigger bets, prioritising mature companies with strong IP and patents over early-stage plays.
This trend toward fewer, larger deals suggests the market is stabilising around high-quality, high-impact opportunities.
Investment trends and market dynamics: Platforms win, point solutions lag
The sector is buzzing with innovation, but not all tech is created equal in the eyes of VCs.
Right now, it’s all about AI-driven discovery tools, computational biology, and synthetic bio.
Instead of flashy breakthroughs, investors want versatile platforms: tools that can apply across use cases, not just single-problem solvers.
This shift is driving consolidation, as companies with broader applications attract more capital and acquisition interest.
Some themes emerging from the report:
- AI is everywhere: From molecular prediction to programmable biology, startups are embedding AI deep into the R&D stack.
- Lab automation and advanced computational tools are rising stars. Think fully integrated, data-rich labs of the future.
- Multiomics diagnostics (layering genomics, proteomics, etc.) are climbing fast, fueled by the rise in personalised medicine.
- Spatial biology, single-cell analysis, and AI-powered lab systems are climbing investor priority lists, showing the industry’s push toward fully integrated, data-driven R&D.
Meanwhile, strategic M&A is heating up. Established players like Thermo Fisher and Danaher are acquiring mature platforms, while venture capital dollars are increasingly being invested in emerging technologies.
If you’re not building something broad and integrable, you’re at risk of being left behind.
Notable Q1 2025 VC deals
The first quarter delivered big-ticket funding events, with AI continuing to command investor attention:
Megarounds ($100M+)
- Colossal Biosciences: $200M Series C (CRISPR de-extinction tech) at $10.2B valuation
- Harrison.ai: $111.8M Series C (AI-powered healthcare integration tools)
- Geneoscopy: $105M Series C (digestive disease diagnostics) at $440M valuation
AI’s breakout stars
- Chai Discovery: $60M (molecular-structure prediction AI)
- Bioptimus: $41.4M (universal AI foundation model for biology)
- Latent labs: $39.9M (generative AI for programmable biology)
- Zafrens: $23M (cell-drug interaction mapping)
Specialised tech standouts
- Stellaromics (spatial bio)
- Quibim (multi-omics diagnostics)
- Atrandi (microfluidics)
- Wheeler Bio & Exothera (biomanufacturing)
Exit activity: IPO on pause and M&A on the rise
Here’s the sobering bit: exits are still slow.
Q1 2025 had just six exits totaling $0.2B, far from the blockbuster $47B peak (46 deals) of 2021.
What is making exits this slow?
- Strategic acquisitions ruled the quarter, accounting for five of the six exits. Big players are absorbing innovation, not competing with it.
- The lone public listing came from Sepax Technologies, which raised $217 million in an IPO for its chromatography products. A decent debut, but a rare exception.
- Other acquired companies, including SeQure DX, Eagle Genomics, Asia Genomics, and others, saw undisclosed deal terms, hinting at portfolio-enhancing moves by strategic buyers rather than blockbuster exits.
What is driving the market?
- Consolidation focus: Buyers are snapping up genomics, diagnostics, and analytical tools to round out their offerings.
- Liquidity crunch: Exit activity remains well below 2020-2022 levels when quarterly exits routinely topped $8 billion.
- IPO drought: Liquidity is scarce so strategic M&A becomes the default route.
- Valuation realism: Prices are more grounded now than during the 2021 highs.
- Platform pressure: Companies need to prove they can scale across multiple applications.
With IPOs still scarce, strategic M&A is now the default exit path for biotools companies.
Current landscape snapshot
The data shows VC investment in pharma biotech hit its stride in Q1 2024, with oncology dominating deal value- unsurprising given the sector’s relentless innovation.
Most capital is flowing into early-stage clinical development (Phase 1/2), where the risk-reward balance attracts bold bets.
On the exit front, values peaked alongside investments in early 2024 but have since softened. The preferred path out: M&A deals far outpace IPOs, as acquisitions offer strategic buyers—not just liquidity—making them the safer bet in today’s market.
Oncology and rare disease startups continue to command premium prices, reflecting their high unmet needs and commercial potential.
2025 Outlook: Adapt or get acquired
The biotools sector is entering 2025 with a clear investment mantra: bigger bets on proven winners.
Capital will continue flowing toward established platforms that can demonstrate:
- Validated performance with real-world data
- Multi-application capabilities (versus single-product solutions)
- Clear commercialisation pathways
M&A will remain strong
M&A has become the only game in town, accelerating industry consolidation as buyers cherry-pick assets that can deliver immediate value. Key factors driving this trend:
- Large players like Thermo Fisher and Danaher are sitting on cash reserves and looking to fill technology gaps
- More reasonable valuations compared to 2021-2022 peaks
- The abundance of innovative but capital-constrained targets.
The bottom line
2025 won’t be a return to the boom years but it is not a standstill either. The tools sector is recalibrating:
- Investors want scale: Big checks will flow to platforms that solve multiple problems, not one-off tools.
- Early-stage headwinds persist: Seed funding stays tight as VCs prioritise follow-ons over new bets.
- M&A fills the IPO gap: Strategic buyers, not public markets, will drive liquidity.
It’s a mature, recalibrated market where adaptability wins.
Companies that align with these shifts, whether through partnerships, platform expansion, or fundraising, will thrive. Others may find themselves on the acquisition menu.
-By Alkama Sohail and the AHT Team
